TYENNE 80 mg/4mL
Tocilizumab-aazg · INJECTION, SOLUTION, CONCENTRATE · Fresenius Kabi USA, LLC
TYENNE is a injection, solution, concentrate containing tocilizumab-aazg at 80 mg/4mL, taken intravenous. Manufactured by Fresenius Kabi USA, LLC.
Key Facts
- Brand Name
- TYENNE
- Generic Name
- Tocilizumab-aazg
- NDC Code (Product)
65219-590- Manufacturer
- Fresenius Kabi USA, LLC
- Strength
- 80 mg/4mL
- Dosage Form
- INJECTION, SOLUTION, CONCENTRATE
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761275
- Drug Class
- Interleukin-6 Receptor Antagonist [EPC]
- Marketing Start
- 04/15/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is TYENNE used for?
TYENNE contains Tocilizumab-aazg. It is a injection, solution, concentrate taken intravenous. Consult your doctor for specific uses.
Is TYENNE a controlled substance?
TYENNE is not classified as a controlled substance by the DEA.
What is the generic name for TYENNE?
The generic name for TYENNE is Tocilizumab-aazg. There are no other listed brand versions of Tocilizumab-aazg.
What is the NDC code for TYENNE 80 mg/4mL?
The NDC (National Drug Code) for TYENNE 80 mg/4mL is 65219-590, listed by Fresenius Kabi USA, LLC.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)